Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Begins Study to Identify ALS Biomarkers
December 11, 2018
- Shionogi, Ube Join Hands on Respiratory Syncytial Virus Research
December 11, 2018
- Daiichi Sankyo Grabs Top Spot in Combined Approach of Sales Reps’ Visits, e-Detailing: Survey
December 11, 2018
- Roche Diagnostics Files PD-L1 Test Kit for Imfinzi in Japan
December 10, 2018
- Tecentriq Filed in Japan for 1st Line SCLC: Chugai
December 10, 2018
- RaQualia Launches New Subsidiary for Commercialization of New Projects
December 10, 2018
- Pfizer Files Rheumatrex for Psoriasis Based on Information in Public Domain
December 10, 2018
- Chugai’s Tecentriq Gets Orphan Status in SCLC, Entrectinib in NTRK-Mutated Solid Tumors
December 7, 2018
- Shionogi Set to Get Its Hands on Vast’s Nitric Oxide-Releasing Antimicrobial Agent
December 7, 2018
- Eisai/UCL’s Anti-Tau Antibody Heading into PI for Alzheimer’s Disease
December 7, 2018
- U3-1402 Racks Up 42.9% Response Rate in Breast Cancer Study: Daiichi Sankyo
December 7, 2018
- Teva Takeda Yakuhin Applies for Pediatric Use for Blopress Based on Information in Public Domain
December 7, 2018
- Fuji Yakuhin, Pfizer to Terminate Copromotion for Topiloric in January
December 7, 2018
- Pfizer to Transfer Antiepileptic Agent Gabapen to Fuji Pharma
December 7, 2018
- Chugai Sues Alexion Japan over Soliris Successor ALXN1210 after US
December 6, 2018
- Amicus Aims to Expand Rare and Intractable Disease Pipeline in Japan
December 6, 2018
- Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold
December 6, 2018
- Takeda Shareholders OK £46 Billion Shire Takeover
December 5, 2018
- Hemlibra Approved in Taiwan for Treatment of Hemophilia A with Inhibitors: Chugai
December 5, 2018
- Gilteritinib Shows High Response Rate in Previously Untreated AML Patients in PI: Astellas
December 5, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…